Loading clinical trials...
Loading clinical trials...
A Randomized Controlled, Phase II Trial Comparing Sintilimab and Pembrolizumab at First-line Setting in Patients With Advanced Non-small Cell Lung Cancer
Conditions
Interventions
Sintilimab
Pembrolizumab
Start Date
March 1, 2020
Primary Completion Date
March 1, 2021
Completion Date
December 1, 2021
Last Updated
February 5, 2020
NCT07486219
NCT06305754
NCT05098132
NCT06731413
NCT04585750
NCT05987644
Lead Sponsor
Guangdong Association of Clinical Trials
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions